Independent European source of exatecan will expand choice and strengthen supply resilience for ADC developers Gram-scale material available, with...
Biomapas, a leading integrated life sciences services provider, announces the acquisition of Pinnaxis, a global pharmacovigilance technology and consulting...
Ofichem has signed an agreement to acquire Kinentia Biosciences, a Drug Substance CDMO based in Rensselaer, New York. Completion of the transaction remains...
New capabilities enable researchers to analyse, characterise and prioritise antibody candidates at scale Integrated AI models and workflows suppor...
Ensera, a global CDMO specializing in commercialization support for injectable drug programs, has launched the Ensera Alliance Network, bringing together l...
Fenebrutinib cut relapses by 51% and 58% vs teriflunomide in Phase III RMS trials (FENhance 1 & 2) while showing a consistent, positive trend in dela...
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercializat...
KIT2014 is a novel inhaled peptide therapy being developed for respiratory diseases including chronic obstructive pulmonary disease (COPD), non-CF bronch...
Quotient Sciences, a global integrated CRDMO (contract research, development and manufacturing organization), and Acesion Pharma, a Copenhagen-base...
Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, announced an agreement with ...
Grünenthal, a global leader in pain management and research, and DKSH Business Unit Healthcare, a strategic healthcare business partner and leading pr...
InSilicoTrials, a cloud-based platform for AI and computational modeling and simulation in healthcare, today announced that it is a subawardee on a team ...
Marsico Pancreatic Cancer Initiative at CU Anschutz expands across institutions, pairing single-cell and spatial profiles with longitudinal outcomes fr...
If approved, Joenja would be available to eligible patients aged 4 years and older with APDS who weigh 13 kg or more Decision follows recent approval ...
© 2026 Biopharma Boardroom. All Rights Reserved.
